Exhibit 99.1
FOR IMMEDIATE RELEASE
INTROGEN THERAPEUTICS, INC. ANNOUNCES PROPOSED COMMON STOCK OFFERING
AUSTIN, TX, March 5, 2004 —Introgen Therapeutics, Inc. (NASDAQ: INGN) today announced plans to offer 5.5 million shares of common stock in an underwritten public offering under its existing shelf registration statement. The underwriters will have an option to purchase an additional 825,000 shares to cover over-allotments, if any.
UBS Securities LLC is acting as the sole book-running manager in this offering. SG Cowen and Leerink Swann and Company are acting as co-managers.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities. This offering of shares of common stock may be made only by means of a prospectus supplement and accompanying prospectus. Copies of the prospectus supplement and the accompanying prospectus can be obtained from UBS Securities LLC, 299 Park Avenue, New York, NY 10171.
Introgen is a leading developer of biopharmaceutical products designed to induce therapeutic protein expression using non-integrating gene agents for the treatment of cancer and other diseases. Introgen maintains integrated research, development, manufacturing, clinical and regulatory departments and operates a commercial-scale, CGMP manufacturing facility.
Certain statements in this press release that are not strictly historical may be “forward-looking” statements, which are based on current expectations and entail various risks and uncertainties. Such forward-looking statements include, but are not limited to, those relating to risks and uncertainties inherent in the process of offering common stock under the shelf registration statement, as well Introgen’s future success with its clinical development program for cancer and other diseases. There can be no assurance that Introgen will be able to commercially develop gene-based drugs, that necessary regulatory approvals will be obtained or that any clinical trials or studies undertaken will be successful or that the proposed treatments will prove to be safe and/or effective. The actual results may differ from those described in this press release due to risks and uncertainties that exist in Introgen’s operations and business environment, including, but without limitation, Introgen’s stage of product development and the limited experience in the development of gene-based drugs in general, Introgen’s dependence upon proprietary technology and current competition, history of operating losses and accumulated deficits, reliance on collaborative relationships, and uncertainties related to clinical trials, the
safety and efficacy of Introgen’s product candidates, the ability to obtain the appropriate regulatory approvals, patent protection and market acceptance, as well as other risks detailed from time to time in Introgen’s filings with the Securities and Exchange Commission, including its annual report on form 10-K filed with the Securities and Exchange Commission on March 5, 2004 and its prospectus supplement filed with the Securities and Exchange Commission pursuant to rule 424(b)(3) on March 5, 2004. Introgen undertakes no obligation to publicly release the results of any revisions to any forward-looking statements that reflect events or circumstances arising after the date hereof.
###
Editor’s Note: For more information on Introgen Therapeutics, or for a menu of archived press releases, please visit Introgen’s Website at: www.introgen.com.
Contact:
Introgen Therapeutics, Inc.
C. Channing Burke
(512) 708 9310 Ext. 322
Email: c.burke@introgen.com
